Refine your search
93 results found
Licks Attorneys | Brazil | 27 Sep 2023
Brazilian Ministry of Finance releases the Regulatory Impact Analysis (RIA) Report, recommending repealing CMED's Ordinance #2/2004 and the release of guidelines for transparency in the pricing process
The Brazilian Secretariat for Economic Reforms of the current Ministry of Finance (SRE) released, this past week, the Regulatory Impact Analysis…
Taylor Wessing | Germany | 20 Sep 2023
OLG Brandenburg: Infringement of the price fixing for prescription-only medicinal products through granting cash discount for prompt payment
The decision of the Higher Regional Court of Brandenburg (Oberlandesgericht Brandenburg - OLG Brandenburg) of 6 June 2023 (Ref…
Lexology PRO | United Kingdom | 19 Sep 2023
UK tribunal backs CMA in “extremely serious” excessive pricing case
The UK’s antitrust authority rightly fined Auden McKenzie and Actavis UK for inflating the price of hydrocortisone by over 10,000% but was wrong to sanction another company as part of its decision, the Competition Appeal Tribunal has ruled.
Lexology PRO | Australia, Brazil | 14 Sep 2023
Boehringer Ingelheim first to break ranks in Brazilian cartel probe
Drugmaker Boehringer Ingelheim has struck a settlement deal with Brazil’s competition watchdog, agreeing to pay a €4.35 million fine to end a probe into its role in a nearly three-decade-long conspiracy.
Lexology PRO | Australia, Canada, European Union, etc. | 14 Sep 2023
Lexology PRO weekly roundup: 15 Sep
A look at the results of the ECB’s second climate stress test, a checklist for business licensing requirements and videos on how technology is transforming gambling regulation – plus other top content from Lexology PRO.
Licks Attorneys | Brazil | 22 Aug 2023
Brazilian Antitrust Authority dismisses investigation into alleged “term extension” of pharmaceutical-related patents, indicating position in favor of patent holders
Recently, the Brazilian Antitrust Authority (Administrative Council for Economic Defense - CADE) decided to dismiss a complaint filed by Apsen…
K&S Partners | India | 2 Aug 2023
Divisional applications must have basis in original claims
In Boehringer Ingelheim International GMBH v The Controller of Patents, the Delhi High Court ruled that a divisional application with new claims based on disclosures in the specification of the parent application cannot be allowed. The Court examined how to ascertain "plurality of invention" and whether a divisional application can be filed for claims when such claims were not a part of the......
K&S Partners | India | 26 Jul 2023
Novartis's divisional application found valid in view of plurality of inventions
In Novartis AG v Controller of Patents and Designs, the Delhi High Court dealt yet again with the validity of divisional applications considering the issue of plurality of distinct inventions. Objections had been filed against certain compounds in Novartis AG's divisional application on the grounds that they lacked unity of invention in the parent application. The Court, however, found that......
Dacheng Shanghai | China | 6 Jul 2023
医药研发合同中常见法律风险
随着医药研发外包（CRO）行业的不断发展，越来越多的医药企业和生物科技企业选择将部分甚至全部的医药研发工作外包至专门从事医药研发业务的服务机构。由于医药研发所特有的高投入、高风险的特点…
Lexology PRO | China | 31 May 2023
China issues first joint cartel and abuse fine to epinephrine maker
China’s competition authority has for the first time ever sanctioned a company for cartel conduct and abuse of dominance in a single case – slapping an active pharmaceutical ingredient supplier with a €37.7 million penalty.
